Millennium Management
BTAI icon

Millennium Management’s BioXcel Therapeutics BTAI Stock Holding History

Millennium Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Buy
1,936,760
+101,568
+6% +$167K ﹤0.01% 3614
2025
Q4 		$2.94M Buy
1,835,192
+807,139
+79% +$1.66M ﹤0.01% 3583
2025
Q3 		$2.63M Buy
+1,028,053
New +$3.24M ﹤0.01% 3793
2025
Q1 		– Sell
-6,561
Closed -$39.2K – 5887
2024
Q4 		$39.2K Sell
6,561
-1,487
-18% -$12.4K ﹤0.01% 5626
2024
Q3 		$78.6K Buy
8,048
+376
+5% +$5.05K ﹤0.01% 5622
2024
Q2 		$157K Buy
7,672
+4,852
+172% +$162K ﹤0.01% 5222
2024
Q1 		$127K Sell
2,820
-2,677
-49% -$128K ﹤0.01% 5518
2023
Q4 		$259K Sell
5,497
-3,714
-40% -$206K ﹤0.01% 5041
2023
Q3 		$373K Buy
+9,211
New +$931K ﹤0.01% 4822
2022
Q3 		– Sell
-11,784
Closed -$2.49M – 7076
2022
Q2 		$2.49M Buy
11,784
+10,572
+872% +$2.22M ﹤0.01% 3479
2022
Q1 		$405K Buy
1,212
+9
+0.7% +$2.61K ﹤0.01% 5284
2021
Q4 		$391K Buy
+1,203
New +$516K ﹤0.01% 5278
2021
Q2 		– Sell
-912
Closed -$630K – 6546
2021
Q1 		$630K Sell
912
-2,910
-76% -$2.34M ﹤0.01% 4629
2020
Q4 		$2.83M Sell
3,822
-1,373
-26% -$1.07M ﹤0.01% 2947
2020
Q3 		$3.6K Buy
5,195
+3,122
+151% +$2.34M ﹤0.01% 2111
2020
Q2 		$1.76M Buy
+2,073
New +$1.35M ﹤0.01% 2627
2019
Q2 		– Sell
-804
Closed -$127K – 4073
2019
Q1 		$127K Buy
+804
New +$99.1K ﹤0.01% 3815
2018
Q3 		– Sell
-2,862
Closed -$421K – 3908
2018
Q2 		$421K Buy
2,862
+931
+48% +$142K ﹤0.01% 3244
2018
Q1 		$316K Buy
+1,931
New +$322K ﹤0.01% 3193

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's BTAI Position: Q1 2026 in Review

Millennium Management increased its BioXcel Therapeutics (BTAI) stake by 5.5% in Q1 2026, buying an estimated $167K and bringing the position to 1,936,760 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Millennium Management first reported a position in BTAI in Q1 2018 and has held it in 19 quarters since. The position peaked at $2.94M in Q4 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Millennium Management held 1,936,760 shares of BioXcel Therapeutics worth $2.6M as of Q1 2026.
  • Millennium Management bought 101,568 BioXcel Therapeutics shares in Q1 2026, an estimated $167K.
  • BioXcel Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3614 holding.
  • Millennium Management first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 19 quarters since.
  • Millennium Management's BioXcel Therapeutics position peaked at $2.94M in Q4 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.